NVCR News and Press, NovoCure Limited From 08/28/23

2023-08-28 10:05:32 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...

2023-08-28 08:16:32 ET More on pre-market losers: AMC Crash Limits Turnaround Potential AMC: Bankruptcy Is Almost Certain Stocks To Watch: Spotlight On Nvidia, AMC Entertainment, Snowflake, Twilio And DICK'S Sporting Goods AMC Entertainment's APE Conversion: ...

2023-08-28 07:54:18 ET More on NovoCure NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum NovoCure: Uncertain Regulatory Path And Slowing Growth NovoCure Limited ( NVCR ) Q2 2023 Earnings Call Transcript NovoCure Limited 2023 Q2 - Re...

Novocure (NASDAQ: NVCR) today announced that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival (OS) at the final analys...

2023-08-23 09:04:00 ET Summary NovoCure sells and develops devices intended to treat solid tumor cancers using physical forces related to electric fields. The firm’s sales growth ended in Q3-2020, and since then operating and net margins (LTM) have been deteriorating. Its n...

San Diego, California--(Newsfile Corp. - August 12, 2023) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NovoCure Limited (NASDAQ: NVCR) securities between January 5, 2023 and June 5, 2023, all dates inclusive (the "Class Period") have until A...

2023-08-09 10:45:00 ET Growth stocks have been top performers in 2023 after lagging behind value and dividend stocks in 2022. And despite the signs of a slowing global economy, growth stocks are expected to maintain their momentum in the near future, thanks to the sharp pullback in this ass...

2023-08-09 05:10:00 ET When it comes to oncology therapies, most people probably think about drugs, but NovoCure (NASDAQ: NVCR) has a radically different approach. Its portable anti-cancer device is already on the market, and it appears to be a helpful add-on treatment for glioblast...

2023-08-08 16:11:00 ET Cancer-focused biotech Novocure (NASDAQ: NVCR) was the focus of an analyst upgrade on Tuesday, and the stock benefited from the move. In late-session trading that day, it was up by more than 3.3% in price, in contrast to the 0.5% slump of the bellwether S&am...

2023-08-08 14:20:40 ET More on NovoCure NovoCure: Uncertain Regulatory Path And Slowing Growth NovoCure At 5 Year Lows: Avoid Or Opportunity? NovoCure upgraded at Wedbush citing balanced risk-reward setup Why did NovoCure stock crash today? TTFields data ...